-
公开(公告)号：US20190023757A1
公开(公告)日：2019-01-24
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
公开(公告)号：US20170183391A9
公开(公告)日：2017-06-29
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
4.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
5.发明申请VARIANT FC-POLYPEPTIDES WITH ENHANCED BINDING TO THE NEONATAL FC RECEPTOR 有权具有与NEONATAL FC受体增强结合的变体FC-多聚体公开(公告)号：US20140356358A1
公开(公告)日：2014-12-04
申请号：US14367183
申请日：2012-12-17
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Seog Joon Han , Susie M. Harris , Randal R Ketchem , Ji Lu , Mark L Michaels , Marc W Retter , Mei-Mei Tsai
CPC classification number: C07K16/28 , C07K16/00 , C07K2317/30 , C07K2317/524 , C07K2317/526 , C07K2317/72 , C07K2317/90 , C07K2317/94 , G01N33/6857 , G01N2333/705
Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
Abstract translation: 本文描述的是变体Fc片段，其在pH 5-6处具有更高亲和力和/或更高结合活性的结合于新生儿Fc受体（FcRn）的环内或邻近的插入，并且在 生理pH与对照Fc片段相比，即在生理pH下几乎没有或没有结合活性。 还描述了包含这些变体Fc片段的变体Fc-多肽。 进一步描述了制备和鉴定此类Fc片段的方法以及制备和使用该Fc-多肽的方法。
-
Patent Agency Ranking
公开(公告)号：US20250136653A1
公开(公告)日：2025-05-01
申请号：US18737435
申请日：2024-06-07
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20240076333A1
公开(公告)日：2024-03-07
申请号：US18499499
申请日：2023-11-01
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , JIng Xu
CPC classification number: C07K14/50 , A61K38/1825 , A61K2039/505
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20180072791A1
公开(公告)日：2018-03-15
申请号：US15714726
申请日：2017-09-25
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Hui-Quan Han , Keith Soo-Nyung Kwak , Xiaolan Zhou
CPC classification number: C07K14/71 , A61K38/00 , C07K2319/00 , C07K2319/30
Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
-
公开(公告)号：US09273106B2
公开(公告)日：2016-03-01
申请号：US14134482
申请日：2013-12-19
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
Abstract translation: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。
-
10.发明申请VARIANT ACTIVIN RECEPTOR POLYPEPTIDES, ALONE OR IN COMBINATION WITH CHEMOTHERAPY, AND USES THEREOF 有权各种激素受体多肽，单独或与化疗相结合，及其用途公开(公告)号：US20140348827A1
公开(公告)日：2014-11-27
申请号：US14366978
申请日：2012-12-19
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Huiquan Han , Keith Soo-Nyung Kwak , Xiaolan Zhou
IPC: A61K38/17 , A61K39/395 , A61K31/4164 , A61K45/06 , A61K31/7072
CPC classification number: A61K38/179 , A61K31/4164 , A61K31/513 , A61K31/655 , A61K31/7072 , A61K31/7088 , A61K39/395 , A61K45/06 , C07K14/71 , A61K2300/00
Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Abstract translation: 本发明提供了能够结合和抑制活化素A，肌生成抑制素或GDF-11的活性的变体激活素IIB可溶性受体多肽和蛋白质。 本发明还提供能够产生变体多肽和蛋白质的多核苷酸，载体和宿主细胞。 还提供了用于治疗肌肉消瘦等疾病和病症的组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.034 seconds)
